FY2018 EPS Estimates for Amedisys Inc Boosted by Analyst (AMED)

Amedisys Inc (NASDAQ:AMED) – Equities researchers at Oppenheimer increased their FY2018 earnings estimates for Amedisys in a research report issued to clients and investors on Tuesday, October 30th. Oppenheimer analyst M. Wiederhorn now expects that the health services provider will post earnings per share of $3.57 for the year, up from their previous estimate of $3.39. Oppenheimer also issued estimates for Amedisys’ Q4 2018 earnings at $0.84 EPS, Q1 2019 earnings at $0.91 EPS, Q2 2019 earnings at $1.05 EPS, Q3 2019 earnings at $0.97 EPS, Q4 2019 earnings at $1.06 EPS and FY2019 earnings at $3.99 EPS.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Monday, October 29th. The health services provider reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.18. The firm had revenue of $417.34 million during the quarter, compared to analysts’ expectations of $411.05 million. Amedisys had a net margin of 5.39% and a return on equity of 22.72%. The company’s revenue for the quarter was up 11.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.56 earnings per share.



A number of other analysts have also recently issued reports on the stock. Bank of America set a $139.00 target price on shares of Amedisys and gave the stock a “buy” rating in a research note on Tuesday, September 18th. Cantor Fitzgerald began coverage on shares of Amedisys in a research note on Thursday, September 13th. They set a “neutral” rating and a $117.00 target price for the company. Canaccord Genuity began coverage on shares of Amedisys in a research note on Thursday, September 13th. They set a “neutral” rating and a $117.00 target price for the company. SunTrust Banks raised their target price on shares of Amedisys to $130.00 and gave the stock a “buy” rating in a research note on Thursday, October 11th. Finally, Robert W. Baird raised their target price on shares of Amedisys from $105.00 to $120.00 and gave the stock a “neutral” rating in a research note on Thursday, October 11th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Amedisys has an average rating of “Buy” and a consensus price target of $102.38.

Shares of AMED stock opened at $115.18 on Wednesday. The firm has a market capitalization of $3.13 billion, a price-to-earnings ratio of 52.12, a PEG ratio of 1.54 and a beta of 1.00. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.30. Amedisys has a one year low of $45.60 and a one year high of $127.38.

In related news, insider David B. Pearce sold 398 shares of the firm’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $121.71, for a total transaction of $48,440.58. Following the transaction, the insider now directly owns 11,818 shares of the company’s stock, valued at $1,438,368.78. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.60% of the stock is currently owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the stock. Aperio Group LLC increased its position in Amedisys by 2.7% during the third quarter. Aperio Group LLC now owns 18,559 shares of the health services provider’s stock worth $2,319,000 after acquiring an additional 480 shares during the period. Amalgamated Bank increased its position in Amedisys by 13.7% during the second quarter. Amalgamated Bank now owns 4,667 shares of the health services provider’s stock worth $399,000 after acquiring an additional 563 shares during the period. Piedmont Investment Advisors LLC increased its holdings in Amedisys by 9.3% in the 2nd quarter. Piedmont Investment Advisors LLC now owns 6,668 shares of the health services provider’s stock valued at $570,000 after buying an additional 567 shares during the period. Metropolitan Life Insurance Co. NY increased its holdings in Amedisys by 6.9% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 9,282 shares of the health services provider’s stock valued at $793,000 after buying an additional 596 shares during the period. Finally, Xact Kapitalforvaltning AB increased its holdings in Amedisys by 14.1% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 4,851 shares of the health services provider’s stock valued at $415,000 after buying an additional 600 shares during the period. 93.19% of the stock is currently owned by institutional investors and hedge funds.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

See Also: What are retained earnings?

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply